Colon Cancer
Conditions
Interventions
None listed
Sponsors
National Defense Medical College and Kyushu University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients who underwent curative resection (R0) of stage II or stage III colon cancer (including rectosigmoid cancer), with lymph node dissection (D2 or D3), from 2009 to 2012. (2) Patients aged 20- 79 years. (3) Patients who were histologically diagnosed with primary Stage II colon adenocarcinoma and did not receive adjuvant chemotherapy, and patients who were histologically diagnosed with primary Stage III colon adenocarcinoma and received adjuvant chemotherapy.
Exclusion criteria
Exclusion criteria: (1) Patients who had received preoperative therapy. (2) Patients with a previous malignancy, within 5 years of operation, except for tumors at the stage of carcinoma in situ. (3) Patients who had recurrence or died within 60 days of surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To examine the relationship between recurrence risk stratification using 55-gene classifier (55GC) and RAS mutation, and recurrence-free, disease-free or overall survival in stage II and stage III colon cancer cases. | — |
Secondary
| Measure | Time frame |
|---|---|
| To examine the significance of clinicopathological factors, gene mutations, and multiplex genomic tests as predictors of colon cancer recurrence risk. To investigate the novelty and independence of the 55-gene classifier and RAS family mutation as a risk factor. To examine whether novel procedures can evaluate the effect of oxaliplatin-based adjuvant chemotherapy. | — |
Countries
Japan
Contacts
Public ContactEiji SHINTO
National Defense Medical College Department of Surgery
Outcome results
None listed